和黃醫藥(00013.HK)治療直腸癌藥物全球III期研究達總生存期主要終點
和黃醫藥(00013.HK)公布,(口夫)(口奎)替尼用於探索性治療晚期難治性的轉移性結直腸癌的FRESCO-2關鍵性全球III期研究的已達到總生存期(OS)這一主要終點。
FRESCO-2研究是一項在美國、歐洲、日本及澳洲開展的全球多中心臨床試驗,旨在探索(口夫)(口奎)替尼加最佳支持治療對比安慰劑加最佳支持治療用於治療標準化療及相關生物製劑治療後疾病進展或對TAS-102和/或瑞戈非尼(regorafenib)不耐受的轉移性結直腸癌患者。除OS外,關鍵次要終點無進展生存期(PFS)亦觀察到具有統計學意義的顯著改善。(口夫)(口奎)替尼的安全性與先前臨床試驗中觀察到的一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.